Cite
HARVARD Citation
Badibouidi, F. et al. (n.d.). 4CPS-072 Comparison of immune checkpoint inhibitors (nivolumab, pembrolizumab, atézolizumab and durvalumab) in the treatment of non-small cell lung cancer: tolerance and financial impact. European journal of hospital pharmacy. p. A81. [Online].